ADARx Pharmaceuticals, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 25 | Q2 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|
| – | – | -107.2% | – | |
| – | +21.8% | +15.0% | +2.1% | |
| – | -33.8% | -27.0% | +79.9% | |
| – | +20,091.4% | -100.4% | – | |
| – | +99.6% | -92.2% | +376.6% | |
| – | – | -97.6% | +200.0% | |
| – | +3,992.6% | -105.3% | – | |
| – | – | -107.3% | – |
Data as of: November 16, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.